Friday, July 10, 2026

Drug profile · INN

oseltamivir

oseltamivir (EBILFUMIN) is an FDA-listed pharmaceutical active ingredient.

EMA: approved NMPA: clinical trials Antiinfectives for systemic use (J05) J05AH02
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — oseltamivir
Class
Antiinfectives for systemic use (J05)
Route
Patents
0
Programs
4
Data quality
0.83

Quick answer

oseltamivir (EBILFUMIN) is an FDA-listed pharmaceutical active ingredient.

Key facts

INN oseltamivir
Brand EBILFUMIN
Therapeutic class Antiinfectives for systemic use (J05)
ATC code J05AH02

Approval history

Authority Status Date
EMA approved
NMPA clinical trials

Pipeline programs

  1. APHP210090 Phase 3 · PARItec · Adult patients admitted to the ICU for management of severe
  2. ASC09F+Oseltamivir Phase 3 · Tongji Hospital · 2019-nCoV Pneumonia
  3. FLUDEX Phase 3 · George Institute for · Severe Influenza
  4. NCT02735707 Phase 3 · Disc Medicine · Respiratory tract infection

Related & competitor drugs

  1. atazanavir sulfate Antiinfectives for systemic use (J05)
  2. colistimethate sodium Antiinfectives for systemic use (J01)
  3. covid-19 mrna vaccine Antiinfectives for systemic use (J07)
  4. daptomycin Antiinfectives for systemic use (J01)
  5. darunavir Antiinfectives for systemic use (J05)
  6. dengue tetravalent vaccine (live, attenuated) Antiinfectives for systemic use (J07)

Frequently asked questions

What is oseltamivir?

oseltamivir (EBILFUMIN) is an FDA-listed pharmaceutical active ingredient.

What is the brand name for oseltamivir?

EBILFUMIN is a marketed brand name for oseltamivir. Check FDA Drugs@FDA for the current US label holder and prescribing information.